1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?

On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (BIIB 1.82%) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311. One driver for that anticipated growth is the company's newly launched drug called Leqembi, which aims to treat Alzheimer's disease. But Leqembi is just one of four recent launches, with the other medicines treating conditions like postpartum depression and amyotrophic lateral sclerosis (ALS).Schmidt is likely to ...